SP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
Alirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
About 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential of synthetic biology and digitalization.
The adage you are what you eat is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. Its now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofis antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Company Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.
Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.